U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H23ClN2O3.ClH
Molecular Weight 447.354
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOLABEGRON HYDROCHLORIDE

SMILES

Cl.O[C@@H](CNCCNC1=CC=CC(=C1)C2=CC=CC(=C2)C(O)=O)C3=CC=CC(Cl)=C3

InChI

InChIKey=PMXCGBVBIRYFPR-FTBISJDPSA-N
InChI=1S/C23H23ClN2O3.ClH/c24-20-8-2-6-18(13-20)22(27)15-25-10-11-26-21-9-3-5-17(14-21)16-4-1-7-19(12-16)23(28)29;/h1-9,12-14,22,25-27H,10-11,15H2,(H,28,29);1H/t22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C23H23ClN2O3
Molecular Weight 410.893
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Solabegron (GW427353), a beta-3 adrenoceptor agonist, is in development with AltheRx (now Velicept Therapeutics) for the treatment of irritable bowel syndrome (IBS) and overactive bladder (OAB). Solabegron was discovered and first developed by GlaxoSmithKline. It was acquired by AltheRx, which merged with Velicept in 2015 to continue development of the program. Solabegron has been tested in over 800 study subjects in a twice-a-day formulation and demonstrated efficacy in the treatment of OAB as well as IBS. A once daily formulation designed to optimize patient convenience as well as efficacy has been developed and is currently being evaluated in a phase 2b dose ranging clinical trial. A Phase 2b dose ranging study with the twice daily formulation also began enrollment in Q1 2018.

Approval Year

PubMed

PubMed

TitleDatePubMed
A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
2012 Nov
Patents

Sample Use Guides

Women with OAB: Solabegron 50 mg (n=88), solabegron 125 mg (n=85), or placebo (n=85)-all twice daily-were administered. Solabegron 125 mg produced a statistically significant difference in percent change from baseline to week 8 in incontinence episodes over 24h when compared with placebo. Solabegron 125 mg treatment also showed statistically significant reductions from baseline to weeks 4 and 8 in micturitions over 24 h and a statistically significant increase from baseline to week 8 in urine volume voided.
Route of Administration: Oral
Solabegron (GW427353) stimulated cAMP accumulation in Chinese hamster ovary cells expressing the human beta3-AR, with an EC50 value of 22 +/- 6 nM and an intrinsic activity 90% of isoproterenol. At concentrations of 10,000 nM, GW427353 produced a minimal response in cells expressing either beta1-ARs or beta2-ARs (maximum response <10% of that to isoproterenol).
Substance Class Chemical
Created
by admin
on Thu Jul 06 01:42:58 UTC 2023
Edited
by admin
on Thu Jul 06 01:42:58 UTC 2023
Record UNII
GU14FR8D4A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOLABEGRON HYDROCHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
Solabegron hydrochloride [WHO-DD]
Common Name English
3'-((2-(((2R)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)ETHYL)AMINO)BIPHENYL-3-CARBOXYLIC ACID HYDROCHLORIDE
Systematic Name English
GW427353B
Code English
(1,1'-BIPHENYL)-3-CARBOXYLIC ACID, 3'-((2-(((2R)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)ETHYL)AMINO)-, HYDROCHLORIDE
Common Name English
SOLABEGRON HYDROCHLORIDE [USAN]
Common Name English
GW-427353B
Code English
Classification Tree Code System Code
NCI_THESAURUS C48149
Created by admin on Thu Jul 06 01:42:58 UTC 2023 , Edited by admin on Thu Jul 06 01:42:58 UTC 2023
Code System Code Type Description
DRUG BANK
DBSALT001800
Created by admin on Thu Jul 06 01:42:58 UTC 2023 , Edited by admin on Thu Jul 06 01:42:58 UTC 2023
PRIMARY
USAN
PP-39
Created by admin on Thu Jul 06 01:42:58 UTC 2023 , Edited by admin on Thu Jul 06 01:42:58 UTC 2023
PRIMARY
EPA CompTox
DTXSID40963347
Created by admin on Thu Jul 06 01:42:58 UTC 2023 , Edited by admin on Thu Jul 06 01:42:58 UTC 2023
PRIMARY
FDA UNII
GU14FR8D4A
Created by admin on Thu Jul 06 01:42:58 UTC 2023 , Edited by admin on Thu Jul 06 01:42:58 UTC 2023
PRIMARY
CAS
451470-34-1
Created by admin on Thu Jul 06 01:42:58 UTC 2023 , Edited by admin on Thu Jul 06 01:42:58 UTC 2023
PRIMARY
ChEMBL
CHEMBL208427
Created by admin on Thu Jul 06 01:42:58 UTC 2023 , Edited by admin on Thu Jul 06 01:42:58 UTC 2023
PRIMARY
PUBCHEM
10297443
Created by admin on Thu Jul 06 01:42:58 UTC 2023 , Edited by admin on Thu Jul 06 01:42:58 UTC 2023
PRIMARY
NCI_THESAURUS
C96755
Created by admin on Thu Jul 06 01:42:58 UTC 2023 , Edited by admin on Thu Jul 06 01:42:58 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY